Common metabolic enzyme could predict cancer immunotherapy benefits—and help more patients respond

medicalxpress - Immunotherapies have transformed cancer treatment by helping the immune system recognize and attack tumors. They work for only about 20% of patients, though, and doctors still struggle to predict who will benefit.

AI Summary: New research identifies a common metabolic enzyme as a potential biomarker predicting benefit from cancer immunotherapy, and investigators propose that controlling intracellular metabolite routing could enhance responses. Together, these findings suggest metabolic pathways are both useful predictors and actionable targets to convert non‑responders into responders.

• Metabolic signals predict and boost immunotherapy responses (5)
• Other related research and expert commentary (8)
• Scaling CAR‑T: access, effects, and biomarker collaborations (3)
• Unmasking tumors: epigenetic and immune reprogramming strategies (4)
• All Other Stories

Metabolic signals predict and boost immunotherapy responses

Other related research and expert commentary

Scaling CAR‑T: access, effects, and biomarker collaborations

Unmasking tumors: epigenetic and immune reprogramming strategies

All Other Stories